87 related articles for article (PubMed ID: 15537833)
1. Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3).
Lakhman SS; Ghosh D; Blanco JG
Drug Metab Dispos; 2005 Feb; 33(2):254-7. PubMed ID: 15537833
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.
Blanco JG; Leisenring WM; Gonzalez-Covarrubias VM; Kawashima TI; Davies SM; Relling MV; Robison LL; Sklar CA; Stovall M; Bhatia S
Cancer; 2008 Jun; 112(12):2789-95. PubMed ID: 18457324
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the substrate-binding site of human carbonyl reductases CBR1 and CBR3 by site-directed mutagenesis.
El-Hawari Y; Favia AD; Pilka ES; Kisiela M; Oppermann U; Martin HJ; Maser E
Chem Biol Interact; 2009 Mar; 178(1-3):234-41. PubMed ID: 19061875
[TBL] [Abstract][Full Text] [Related]
4. A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity.
Gonzalez-Covarrubias V; Ghosh D; Lakhman SS; Pendyala L; Blanco JG
Drug Metab Dispos; 2007 Jun; 35(6):973-80. PubMed ID: 17344335
[TBL] [Abstract][Full Text] [Related]
5. Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism.
Bains OS; Karkling MJ; Lubieniecka JM; Grigliatti TA; Reid RE; Riggs KW
J Pharmacol Exp Ther; 2010 Mar; 332(3):755-63. PubMed ID: 20007405
[TBL] [Abstract][Full Text] [Related]
6. Importance of the substrate-binding loop region of human monomeric carbonyl reductases in catalysis and coenzyme binding.
Miura T; Nishinaka T; Terada T
Life Sci; 2009 Aug; 85(7-8):303-8. PubMed ID: 19555696
[TBL] [Abstract][Full Text] [Related]
7. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.
Blanco JG; Sun CL; Landier W; Chen L; Esparza-Duran D; Leisenring W; Mays A; Friedman DL; Ginsberg JP; Hudson MM; Neglia JP; Oeffinger KC; Ritchey AK; Villaluna D; Relling MV; Bhatia S
J Clin Oncol; 2012 May; 30(13):1415-21. PubMed ID: 22124095
[TBL] [Abstract][Full Text] [Related]
8. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity.
Fan L; Goh BC; Wong CI; Sukri N; Lim SE; Tan SH; Guo JY; Lim R; Yap HL; Khoo YM; Iau P; Lee HS; Lee SC
Pharmacogenet Genomics; 2008 Jul; 18(7):621-31. PubMed ID: 18551042
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the role of the amino acid residue at position 230 for catalysis in monomeric carbonyl reductase 3.
Miura T; Itoh Y; Takada M; Tsutsui H; Yukimura T; Nishinaka T; Terada T
Chem Biol Interact; 2009 Mar; 178(1-3):211-4. PubMed ID: 18983987
[TBL] [Abstract][Full Text] [Related]
10. CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin.
Lang JK; Karthikeyan B; Quiñones-Lombraña A; Blair RH; Early AP; Levine EG; Sharma UC; Blanco JG; O'Connor T
Cardiooncology; 2021 May; 7(1):17. PubMed ID: 33975650
[TBL] [Abstract][Full Text] [Related]
11. Studies on reduction of S-nitrosoglutathione by human carbonyl reductases 1 and 3.
Staab CA; Hartmanová T; El-Hawari Y; Ebert B; Kisiela M; Wsol V; Martin HJ; Maser E
Chem Biol Interact; 2011 May; 191(1-3):95-103. PubMed ID: 21256830
[TBL] [Abstract][Full Text] [Related]
12. Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS; Grigliatti TA; Reid RE; Riggs KW
J Pharmacol Exp Ther; 2010 Dec; 335(3):533-45. PubMed ID: 20837989
[TBL] [Abstract][Full Text] [Related]
13. CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients.
Lal S; Sandanaraj E; Wong ZW; Ang PC; Wong NS; Lee EJ; Chowbay B
Cancer Sci; 2008 Oct; 99(10):2045-54. PubMed ID: 19016765
[TBL] [Abstract][Full Text] [Related]
14. Identification of the promoter of human carbonyl reductase 3 (CBR3) and impact of common promoter polymorphisms on hepatic CBR3 mRNA expression.
Zhang J; Blanco JG
Pharm Res; 2009 Sep; 26(9):2209-15. PubMed ID: 19590938
[TBL] [Abstract][Full Text] [Related]
15. Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS; Karkling MJ; Grigliatti TA; Reid RE; Riggs KW
Drug Metab Dispos; 2009 May; 37(5):1107-14. PubMed ID: 19204081
[TBL] [Abstract][Full Text] [Related]
16. A conserved antioxidant response element (ARE) in the promoter of human carbonyl reductase 3 (CBR3) mediates induction by the master redox switch Nrf2.
Cheng Q; Kalabus JL; Zhang J; Blanco JG
Biochem Pharmacol; 2012 Jan; 83(1):139-48. PubMed ID: 22001310
[TBL] [Abstract][Full Text] [Related]
17. Carbonyl Reductase 1 Plays a Significant Role in Converting Doxorubicin to Cardiotoxic Doxorubicinol in Mouse Liver, but the Majority of the Doxorubicinol-Forming Activity Remains Unidentified.
Breysse DH; Boone RM; Long CM; Merrill ME; Schaupp CM; White CC; Kavanagh TJ; Schmidt EE; Merrill GF
Drug Metab Dispos; 2020 Mar; 48(3):187-197. PubMed ID: 31955137
[TBL] [Abstract][Full Text] [Related]
18. Expression of human carbonyl reductase 3 (CBR3; SDR21C2) is inducible by pro-inflammatory stimuli.
Malátková P; Ebert B; Wsól V; Maser E
Biochem Biophys Res Commun; 2012 Apr; 420(2):368-73. PubMed ID: 22425771
[TBL] [Abstract][Full Text] [Related]
19. Human CYP1A1 variants lead to differential eicosapentaenoic acid metabolite patterns.
Schwarz D; Kisselev P; Chernogolov A; Schunck WH; Roots I
Biochem Biophys Res Commun; 2005 Oct; 336(3):779-83. PubMed ID: 16153604
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of doxorubicin to the cardiotoxic metabolite doxorubicinol is increased in a mouse model of chronic glutathione deficiency: A potential role for carbonyl reductase 3.
Schaupp CM; White CC; Merrill GF; Kavanagh TJ
Chem Biol Interact; 2015 Jun; 234():154-61. PubMed ID: 25446851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
